Acumen Pharmaceuticals, Inc. (ABOS) · Oct 26, 2026 · Earnings

Acumen earnings beat, but cash runway ends near pivotal readout

Beat — GAAP EPS $(0.35) vs published consensus around $(0.39)

Acumen’s Q3 earnings beat the published loss estimate, while cash fell to $78.6 million and ALTITUDE-AD results remain the decisive November catalyst.

Acumen is a clinical-stage Alzheimer’s company with one central value driver: sabirnetug, its Phase 2 antibody aimed at toxic soluble amyloid-beta oligomers, with the broader EBD program still preclinical. The market already knew a late-2026 ALTITUDE-AD readout was coming; this filing narrows that window to November 2026, making the trial result the immediate business-defining event. The company’s prior update also pointed to a late-2026 readout and an early-2027 cash runway.

Metric	Q3 2026	Q3 2025 / prior	Read
GAAP EPS	$(0.35)	$(0.44)	Better year over year; above published consensus around $(0.39)
R&D expense	$21.1M	$22.0M	Lower as trial manufacturing, materials, and CRO costs eased
Operating loss	$(25.8)M	$(26.5)M	Slightly improved
Net cash used in operations, nine months	$(68.9)M	$(96.4)M	Lower burn year over year
Cash, cash equivalents and marketable securities	$78.6M	$110.2M at June 30, 2026	Down $31.6M sequentially
Shares outstanding	72.3M	60.6M at Dec. 31, 2025	Higher after financing and other issuance

The trial catalyst is now more concrete, not more advanced. Acumen says the 542-patient ALTITUDE-AD study remains on track for November, with iADRS as the primary efficacy endpoint and cognitive, safety, and biomarker data expected alongside it. 〔0〕 The timing confirmation is useful, but it is mainly a refinement of an already-public expectation rather than a new clinical result.

The quarterly numbers modestly beat the loss benchmark, but earnings are not the story. GAAP loss per share improved to $0.35 from $0.44 a year earlier, while R&D and operating losses also declined. That is a clean financial beat against the published loss estimate around $0.39, but Acumen has no commercial revenue; the result mostly reflects spending control ahead of the readout rather than evidence of a changed product trajectory.

The funding picture is tighter heading into the decisive event. Cash, cash equivalents, and marketable securities fell to $78.6 million from $110.2 million at June 30, 2026. The company says that balance supports current activities into early 2027. 〔1〕 That should cover the November data event and near-term follow-up, but it leaves limited financial distance beyond the catalyst and raises the likelihood that future development will eventually require additional capital. The balance sheet also shows 72.3 million shares outstanding versus 60.6 million at year-end, while nine-month financing included $35.4 million of net private-placement proceeds, so the runway has already been supported partly by dilution.

The EBD program remains optionality, not an additional near-term value driver. Acumen continues to target a mid-2027 IND filing for a brain-penetrating candidate, but that program is still preclinical and competes for cash with the lead sabirnetug program. 〔2〕

Bottom line: This is a modest earnings beat and a clearer November catalyst, but the business story remains binary around ALTITUDE-AD. The filing advances timing visibility while confirming that cash is becoming a constraint around the same event that must validate the pipeline.

What to watch next

ALTITUDE-AD topline results, November 2026

Original filing on SEC EDGAR

More Acumen Pharmaceuticals, Inc. news

Live · an AI on the whole US market

Breaking down Wall Street's information edge.

A buy-side analyst on every ticker.

It reads every public company's filing the second it drops — decoded into plain English, before it's a headline. The edge every investor deserves, not just the desks.

Trade the facts, not the FOMO.

Every event

8-Ks decoded the moment they file

Every number

Fundamentals, valuation, quality

What's next

Earnings calendar + the analyst view

scroll ↓

From filing to your screen in seconds

AllSight is the fastest.

DETECT

The moment it files

Every public company, around the clock. The AI never blinks and never takes lunch — nothing to set up.

filed 9:41:03 · decoded 9:41:19

DECODE

Plain English — never a call.

The event, the numbers, how it sits vs. expectations — in seconds. The AI decodes it; you pull the trigger.

DELIVER

On your screen, before the bell

Overnight and premarket, it's already read everything. You walk into every session with the setup — not scrambling to find it.

Understand it like a Wall Street analyst. Explained like a friend.

the raw filing — read the original on SEC.gov↗

decoded▸

AllSight · BlackBerry Q2 FY27

Revenue $163.3M vs ~$144M expected; adjusted basic EPS $0.07 vs ~$0.04 consensus — a real upside surprise.Income statement
QNX revenue +27% to $80.3M; segment EBITDA $29.0M from $20.5M. “Record performance… core automotive.”Segment — QNX
Licensing jumped to $22.1M from $6.6M — it amplified the beat, but it's less recurring than QNX, so the quality sits in QNX.Segment — Licensing
FY27 guide lifted to $616–636M rev / $141–158M EBITDA, above the prior $594–621M / $119–139M framework.Guidance
QNX growth, margins, cash and a raised outlook all beat. But licensing amplified it and Secure Comms is flat — net retention 91% from 93%.Segment — Secure Comms

Know a company all the way down.

Not just one filing. AllSight profiles every public company end to end — the numbers, the quality, the insiders, the smart money, the Street. One page, nothing missed.

Price & every insider trade, plotted
A quality score ranked against every peer
40+ valuation & profitability multiples
Where each one sits in its 5-year range
Whole-market insider flow, in real time
Which superinvestors are holding it
Analyst consensus & price target

Live · — filings read this week

AllSight gives you an edge others can't.

One scan before the open, one after the close — every filing on every ticker, already decoded. You walk into every session fully prepared.

Not investment advice · a neutral translation you can check against the original SEC filing

allsight.ai

Events/ANDE/8-K · Earnings

8-K · Item 2.02 · Earnings

The Andersons — a record Renewables quarter that beat profit expectations

Filed Aug 3, 2026ANDE · NASDAQ

AllSight readBeatPriced in▲ 1.8% since filed · reaction agrees

adj. EPS $2.15 vs ~$1.48 consensus

This filing tests whether The Andersons' sharp profit increase reflects broad operating improvement or a one-off renewable-fuels boost. It also separates strong adjusted earnings and cash generation from the quarter's legal and impairment charges.

The quarter was substantially stronger than both last year and the published earnings expectation. Adjusted EPS reached $2.15, versus $0.24 a year earlier and above the published consensus of about $1.48; reported EPS was $1.65. Adjusted EBITDA more than doubled to $140 million, while sales slipped modestly — the improvement came from margins and operating performance rather than higher revenue. Financial Highlights · Statements of Operations

Q2 ($M, exc. per-share)	Q2 2026	Q2 2025	YoY
Sales & merchandising revenue	3,097.7	3,135.9	−1%
Net income (attributable)	56.6	7.9	+48.7
Diluted EPS	1.65	0.23	+1.42
Adjusted EPS	2.15	0.24	+1.91
Adjusted EBITDA	140.3	65.2	+75.1
Agribusiness adj. pretax	20.3	16.8	+3.5
Renewables adj. pretax	88.4	9.6	+78.8
Cash from operations	487.9	299.3	+188.6
Cash from ops (pre-WC)	112.9	42.9	+70.1

Renewables drove nearly all of the upside — the operating backdrop was strong, but the result also benefited materially from tax credits. Renewables' adjusted pretax income rose to $88 million on record production, stronger ethanol margins and merchandising gains. It also received $24 million of 45Z producer tax credits, so this was not solely a repeatable plant-margin improvement; the company did cite healthy export and domestic ethanol demand as supportive. Renewables — Record Q2 · Segment Data

Agribusiness improved, but it was a supporting contributor rather than the main earnings engine. Adjusted pretax income increased to $20 million as fertilizer margins improved and merchandising benefited from commodity-price volatility, despite lower fertilizer volumes. Agribusiness — Improved Q2 · Segment Data

Cash generation improved and funding capacity is comfortable, while reported earnings still absorbed meaningful non-core costs. Operating cash flow was $488 million ($113 million before working-capital changes); capital spending was $76 million. Adjusted EPS excludes $0.50 of legal-settlement, impairment and transaction items, so the $2.15 adjusted result runs ahead of the $1.65 reported. Leverage stays below the <2.5× debt-to-EBITDA target; no new quantified full-year outlook was given. Cash & Liquidity · Adjusted Net Income

Community sentiment · 612 votes

58% bullish

Bull 58%Neu 27%Bear 15%

AllSight

AllSight Pro

A buy-side analyst on every ticker — reading the whole market the second it moves.

It reads every public company's filing the instant it drops and hands you what it means — in plain English, before it's a headline.

The read itself

Not another feed. A buy-side analyst that never sleeps, on everything.

Whole-market breadthevery public company

Not the 20 names CNBC repeats. Every ticker that files — thousands of companies, one AI reading all of them.

Filed-to-decoded in secondsspeed

Filed 9:41:03, decoded 9:41:19. You've got the catalyst while the tape is still moving and the crowd's still on the headline.

Past the headlinedepth

What actually happened, the numbers that matter, how it sits vs what the Street expected, and what it sets up next.

Source-grounded & neutralrigor

Every read traces to the words in the actual filing — click to see them. A translation you can check, never a buy/sell call.

Zero effort to youconvenience

Plain English, one glance. Follow your stocks and the moment any of them files, it's in your pocket — no watching, no digging.

All of it, livePro

Free reads every session once it closes. Pro reads it the moment it files: the whole market, all day, every day.

And then — go deeper

From "what happened" to "is it worth it."

Cheap or dear?Where it trades vs its own valuation history.

The quality score, in fullAll five dimensions, ranked against its sector.

Structure & multi-year trendsRevenue, margins, cash — the hard numbers, decoded.

Insider activityWho inside the company is buying and selling.

Analyst price targetsWhere Wall Street says every name is headed.

The whole company, one pagePrice, ownership, the full read — on any ticker.

Hire your personal buy-side analyst.

Trade one usual slippage for a whole market's rhythm.

Free

forever

Every closed session, on the whole market. The live session and the deep company read stay Pro.

Monthly

$29/mo

billed monthly

Everything, live — every session the moment it files, plus the full company read. Flexible, month to month.

Best value · save 40%

Annual

$17.40/mo

$209 billed yearly

about one slippage a month

Same full access — the whole market live and every company — at the lowest price. 40% off the monthly.

Billed today. Powered by Stripe · AllSight never sees your card.

Acumen earnings beat, but cash runway ends near pivotal readout

What to watch next

More Acumen Pharmaceuticals, Inc. news

Breaking down Wall Street's information edge.